Background: Silicone gel-filled breast implants were developed in 1962 but did not fall under the auspices of the U.S. Food and Drug Administration until 1976 and were not classified as class III devices until 1988. This set the stage for a series of Food and Drug Administration advisory panel meetings and a moratorium on the sale of these implants from 1992 until 2006, when sufficient clinical data were presented to demonstrate their safety. Methods: This study was conducted under the rigorous framework of a Food and Drug Administration-approved investigational device exemption to document the safety and effectiveness of Inamed silicone-filled breast implants through 10 years. Of 940 female subjects, approximately half were augmentation subjects, one-quarter were reconstruction subjects, and one-quarter were revision subjects. Follow-up visits were conducted at 0 to 4 weeks, 6 months, 1 year, and annually thereafter. Approximately one-third of subjects also underwent biennial magnetic resonance imaging evaluation to detect silent rupture. Primary statistical analyses used the Kaplan-Meier product limit method. Results: Data through 6 years are currently available from the 10-year study, with patient follow-up rates for that visit ranging from 78 to 92 percent per cohort. As expected, the most common local complication in all cohorts was capsular contracture, occurring in 15 to 20 percent of subjects. The by-implant rupture rate was 3.5 percent overall at 6 years. Satisfaction with implants was uniformly high throughout the study period, with 6-year rates of 95 percent for augmentation subjects and 94 percent for reconstruction subjects.
S
ilicone gel-filled breast implants first became available in 1962 as a result of Texas plastic surgeons Tom Cronin and Frank Gerow working with Dow Corning. 1 Those first silicone gel-filled breast implants were composed of a fairly thick silicone elastomer outer shell that was filled with a silicone gel. By the time silicone emerged on the breast implant scene, it had already been widely used in industry and medicine since its introduction just before World War II.
Depending on its molecular weight, silicone can be produced as a mist suitable to be a spray lubricant, as a gel, or even as a solid, providing a wide array of uses. Because of its special properties, silicone has been a component in hairspray, infant formula, beer, antacids, and medical grade tubing and has been used as a lubricant around and within hypodermic needles and syringes.
der the Medical Device Amendment to the Food, Drug, and Cosmetic Act to regulate devices and drugs. Appreciating the large number of medical devices already on the market, the U.S. Food and Drug Administration was allowed to grandfather those devices, pending further review. Thus, silicone gel-filled breast implants remained on the market pending such further review. In 1988, the U.S. Food and Drug Administration classified these devices as class III, which set in motion a process by which manufacturers were required to demonstrate safety and effectiveness in a premarket approval application. 2, 3 During the period from 1962 to 1988, several other factors changed. A number of different implant designs and modifications were developed. There were double-lumen, reverse double-lumen, triple-lumen, smooth surface, textured surface, polyurethane-covered, thick shell, thin shell, barrier shell, and implants of varying gel cohesivity. During this time, other manufacturers had joined Dow Corning in the silicone gel implant marketplace.
In 1991, the U.S. Food and Drug Administration held an advisory panel meeting on silicone gel-filled breast implants. One of the implant manufacturers at the panel meeting was McGhan Medical, which would become Inamed Corporation in 2001 and later be acquired by Allergan Corporation in 2006. At that meeting, the panel recommended that McGhan's implants be left on the market for public health reasons pending further studies. Nevertheless, in January of 1992, U.S. Food and Drug Administration commissioner David Kessler declared a "voluntary" moratorium on the sale of silicone breast implants and arranged for a new panel to meet in February of 1992. That panel recommended restricting the sale of silicone breast implants to subjects in research studies (core, adjunct, and urgent need) pending further information. It was not until 1998 that McGhan Medical Corporation received U.S. Food and Drug Administration approval to initiate its core and adjunct studies. 4 In October of 2003, Inamed presented a premarket approval application for its siliconefilled breast implants, and the U.S. Food and Drug Administration advisory panel recommended approval. 4 However, in January of 2004, the U.S. Food and Drug Administration decided to defer approval pending further studies and at the same time published a revised guidance document that set forth additional studies and information that manufacturers would be required to submit to gain approval. 5 At a U.S. Food and Drug Administration panel meeting in April of 2005, Inamed presented additional material in support of its silicone gel premarket approval that was followed by a U.S. Food and Drug Administration "approvable" letter in September of 2005. On November 17, 2006, the U.S. Food and Drug Administration approved Allergan's application to market its Inamed siliconefilled breast implants. 6 The following is a distillation of the most important 6-year data from the core clinical study of these implants.
PATIENTS AND METHODS

Study Design
The most rigorous of all study designs is the U.S. Food and Drug Administration-approved investigational device exemption study, and it was under that framework that this study was conducted. The study was designed as a prospective, multicenter trial to document safety and effectiveness of Inamed silicone-filled breast implants for 10 years after implantation. The protocol specified a total of 940 subjects, with approximately half enrolled for the augmentation indication, onequarter for reconstruction, and one-quarter for revision. Follow-up visits with physical examinations were to be conducted at 0 to 4 weeks, 6 months, 1 year, and annually through 10 years. A subset of approximately one-third of subjects were to enroll in a magnetic resonance imaging substudy in which they underwent magnetic resonance imaging evaluation to detect silent rupture at 1, 3, 5, 7, and 9 years after implantation.
Safety assessments included local complications noted by the physician and secondary operations and explantations (implant removal with or without replacement). Effectiveness was measured by breast size change (augmentation subjects only), subject and physician satisfaction, and quality-of-life scales. A complete examination of the quality-of-life assessments is beyond the scope of this article and will be addressed in another publication.
The study was approved by the relevant institutional review boards, and all subjects signed informed consent. To encourage a high rate of follow-up compliance, both subjects and investigators received financial incentives for adhering to the required visit schedule (see Table, Supplemental Digital Content 1, which displays the Inamed Core Study investigator list, http://links.lww.com/A200).
Subjects
Subjects were eligible to enroll in the study if they were female, aged 18 years or older, had Volume 120, Number 7 Suppl. 1 • Inamed Silicone Breast Implants adequate tissue to cover the implants, and were willing to follow all study requirements. Exclusion criteria were advanced fibrocystic disease considered to be premalignant without accompanying subcutaneous mastectomy; breast cancer without mastectomy; abscess or infection at the time of enrollment; pregnant or nursing; any disease including uncontrolled diabetes that impacts wound healing ability; tissue characteristics that are clinically incompatible with mammaplasty, such as tissue damage resulting from irradiation, inadequate tissue, compromised vascularity, or ulceration; any condition that constitutes an unwarranted surgical risk (e.g., unstable cardiac or pulmonary problems); psychological characteristics that may be incompatible with the surgical procedure and the prosthesis, such as inappropriate attitude or motivation (e.g., body dysmorphic disorder); and unwillingness to undergo further surgery for revision if medically required.
Subjects were to be enrolled in the applicable cohort based on the following indications: augmentation (subject dissatisfaction with breast size or shape, asymmetry, ptosis, aplasia); reconstruction (for the affected breast, mastectomy for cancer or trauma, or prophylactic mastectomy; for the unaffected breast, contralateral asymmetry); and revision (previous augmentation or reconstruction with silicone-filled or saline-filled breast implants). To be eligible to enroll in either the augmentation or reconstruction cohort, subjects could not have undergone any previous breast implant operations.
Statistical Analyses
Data were collected prospectively on standardized case report forms at baseline (preimplantation), scheduled follow-up visits, and unscheduled office visits. Investigators were prompted to report complications by means of check boxes for 35 possible complications plus other, including such expected postoperative sequelae as breast pain, redness, and swelling. Complications were reported with severity levels (i.e., very mild, mild, moderate, severe, or very severe), and only occurrences that were in the moderate, severe, or very severe range were included in the analysis (for capsular contracture, Baker grades III and IV) because the mild and very mild occurrences were not considered to be clinically significant problems. For the implant rupture, implant extrusion, and pneumothorax complications and reoperation and implant removal, all reported occurrences are included in the analysis regardless of the severity rating.
Magnetic resonance imaging results were evaluated separately by a radiologist at the screening facility and by a central reviewer radiologist who provided a consistent assessment across all study sites. Both radiologists were blinded to each other's assessments and to the investigator's evaluation of whether rupture was suspected. Magnetic resonance images were evaluated as either evidence of rupture, no evidence of rupture, or indeterminate or unreadable film (attributable to inadequate views or flawed film). The worst-case rupture status reported by either reviewer was used for data analysis.
Breast dimensions were measured at baseline and at 6 months and 1 year after implantation to ascertain breast size change for augmentation subjects. If measurements were recorded for both of these postoperative visits, the 6-month data were used in the analysis. Satisfaction with the implants was assessed at every follow-up visit both by physicians and by subjects on a five-point scale ranging from definitely satisfied to definitely dissatisfied.
The primary method of analysis for the complication and reoperation data was survival analysis using the Kaplan-Meier product limit method. Data are reported based on the original devices implanted at baseline. If a primary study implant was removed and replaced with another study device, data on the replacement device were not included in the analysis. The only analysis that included subjects with replacement devices was subject satisfaction because that endpoint may be influenced by the occurrence of implant replacement procedures. Rupture rate analyses were based on data collected in the magnetic resonance imaging substudy because these subjects provide the most reliable data on asymptomatic and symptomatic rupture.
RESULTS
Subjects and Surgical Characteristics
The 940 subjects specified in the protocol were enrolled by 33 investigational sites located throughout the United States. However, the results presented here exclude the 225 subjects who underwent implantation with the Style 153 implant, a shaped device that is no longer being manufactured. This provided a population of 455 augmentation subjects, 98 reconstruction subjects, and 162 revision subjects. At the direction of the U.S. Food and Drug Administration, the revision subjects were stratified into separate cohorts depending on whether their original implantation was for augmentation or reconstruction. The result was 147 revision-augmentation subjects and 15 revision-reconstruction subjects. As the revision-reconstruction cohort yielded too few subjects to perform Kaplan-Meier analyses, complication rates are not presented for that group, but no unusual trends were observed that would indicate a vastly different safety profile for these subjects.
Currently, data through 6 years are available from the 10-year study. The majority of subjects were Caucasian and married and had attended college ( Table 1 ). The median age was 34 years for augmentation subjects and 48 years for reconstruction subjects, with their revision counterparts being 6 to 8 years older. The demographic profile was consistent with data on plastic surgery patients reported by the American Society for Aesthetic Plastic Surgery. 7 The majority of augmentation and revisionaugmentation subjects received smooth implants, whereas most reconstruction and revision-reconstruction subjects received textured implants (Table 2). Most of the operations were performed under general anesthesia, with augmentation and revision-augmentation procedures primarily taking place in physicians' offices or surgical facilities and reconstruction and revision-reconstruction operations being performed at a hospital. The majority of the implants were placed in the submuscular position, with surgeons chiefly using the inframammary or periareolar incision sites for augmentation and revision-augmentation subjects and the mastectomy scar or inframammary incision sites for reconstruction and revision-reconstruction subjects.
Despite the multiyear nature of the study, a high rate of follow-up compliance was maintained. Disregarding those subjects who died or had all study devices removed (Ͻ10 percent of subjects), compliance rates for the 6-year visit were 81 percent for augmentation, 78 percent for revisionaugmentation, 90 percent for reconstruction, and 92 percent for revision-reconstruction. Follow-up rates for the third serial magnetic resonance imaging (at year 5) were 91 percent for augmentation, 81 percent for revision-augmentation, 86 percent for reconstruction, and 100 percent for revision-reconstruction.
Safety
As expected, the most common local complication in all cohorts was capsular contracture, occurring in 15 to 20 percent of subjects (Table 3) . The capsular contracture rate was the lowest in augmentation subjects (14.8 percent), followed by reconstruction (15.9 percent) and revision-augmentation (20.5 percent). Other common complications were breast pain and swelling, but these occurred predominantly as postoperative sequelae that resolved within 2 months after surgery. The vast majority of implants (96.5 percent) did not rupture over the 6-year follow-up period, based on KaplanMeier survival analyses (Fig. 1) . This means that the 6-year by-implant rupture rate was 3.5 percent overall and for augmentation implants. Approximately Often mentioned along with local complications are secondary operations and explantations, some of which are performed to address complications. Reoperations were least common for augmentation subjects, at 28.0 percent. Of those augmentation subjects, more than three-quarters (76.2 percent) had only one reoperation through 6 years. The 51.9 percent of reconstruction subjects undergoing reoperation also had approximately three-quarters (72.9 percent) requiring only one reoperation. For the revision-augmentation subjects, 40.3 percent had a reoperation through 6 years, and 60 percent of them needed just one reoperation. The primary reason for reoperation was capsular contracture for augmentation and revision-augmentation subjects and implant malposition for reconstruction subjects (Table 4) . 
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The most common reasons subjects underwent explantation were capsular contracture, patient request for style/size change, and implant malposition. Asymmetry was also a common reason for explantation among reconstruction subjects. More than three-quarters of explanted subjects in each cohort elected to receive a replacement implant, most often another Inamed silicone implant. Twothirds of the augmentation and revision-augmentation subjects who received a replacement Inamed implant opted for a larger size implant, whereas reconstruction subjects did not choose a larger size implant any more often than a smaller size implant.
Effectiveness
Of the 396 augmentation subjects with a valid breast measurement both before and after implantation, the majority of subjects increased the size of their breasts by either one cup size (41 percent) or two cup sizes (45 percent). The remaining subjects increased by more than two cup sizes (8 percent), maintained the same cup size (5 percent), or showed a decrease in cup size (Ͻ1 percent). For these latter subjects, a cup size increase was not observed for a variety of reasons, including the purpose of implant surgery (e.g., to improve the shape and fullness of the breast, to correct congenital asymmetry) and an atypical preimplant breast measurement (e.g., larger than normal cup size because of menstruation).
Satisfaction with the implants was uniformly high throughout the study period for both subjects and physicians in all cohorts. This equated to ratings of satisfied or definitely satisfied on the five-point scale. At 6 years, satisfaction rates were 95 percent for augmentation subjects, 84 percent for revision-augmentation subjects, and 94 percent for reconstruction subjects. Physician satisfaction rates were nearly identical to those of the subjects. The primary reason specified for dissatisfaction by both subjects and physicians was capsular contracture for augmentation and revisionaugmentation and asymmetry for reconstruction.
DISCUSSION
Although silicone gel-filled breast implants have only recently reentered the U.S. market after restricted availability for nearly 15 years (from January of 1992 until November of 2006), they have been available for more than three decades in a significant number of developed countries around the world. Thus, there is a plethora of scientific data available to support the safety of these devices. The National Academy of Science's Institute of Medicine, Judge Pointer's federal panel of independent experts, a number of European oversight agencies, and several major medical professional societies have all gone on record stating there is no compelling evidence that silicone gel-filled implants cause any systemic illness. The focus of this study is on the local Volume 120, Number 7 Suppl. 1 • Inamed Silicone Breast Implants performance of the implants, as it is important for both surgeons and patients to have access to this information. Breast implants are not considered lifelong medical devices. On the basis of the Core Study data, it is clear that 97 percent of implants in place 6 years after a breast augmentation are intact. Eighty-five percent of women having breast augmentation will not have capsular contracture through 6 years. Seventy-two percent of women having breast augmentation will not need a reoperation in the first 6 years. Furthermore, many of the reoperations were for asymmetries, breast ptosis, unrelated surgical complications, implant malposition, cosmetic reasons, and even for biopsies. On the question of effectiveness, 95 percent of the augmentation subjects were satisfied at 6 years.
Interestingly, the capsular contracture rates were similar for augmentation and reconstruction subjects in the Core Study, whereas it is generally accepted that rates are higher for postmastectomy patients than for cosmetic patients. 86, 87 We speculate this may be related to the higher percentage of textured devices and submuscular placement among our reconstruction subjects. These factors, 88, 89 among others, 90, 91 have been correlated with a reduced incidence of capsular contracture and thus warrant further study.
Allergan's Inamed silicone-filled breast implants are now available in the United States for all indications: breast augmentation (for women at least 22 years old), breast augmentation-revision, breast reconstruction and breast reconstructionrevision. Adding to the current body of knowledge, the Core Study will continue for another 4 years, providing valuable 10-year data. As a condition of approval, the U.S. Food and Drug Administration also required additional data that is beyond the scope of the Core Study. Thus, Allergan has developed a breast implant follow-up study designed to track approximately 39,000 women with silicone gel-filled breast implants for 10 years. That study is intended to look for rare adverse events and possible second-generation effects and magnetic resonance imaging and mammography as they might relate to silicone gelfilled breast implants.
In the meantime, surgeons and patients now have more information to guide them in decision making and can be reassured by the safety and high levels of satisfaction with Inamed siliconefilled breast implants at 6 years in vivo. In the coming years, they can be confident of having even more such valuable information with which to make the most informed decision possible.
